| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 133 | 2024 | 4255 | 10.010 |
Why?
|
| HIV Infections | 243 | 2024 | 16715 | 8.740 |
Why?
|
| Reverse Transcriptase Inhibitors | 40 | 2020 | 615 | 5.860 |
Why?
|
| HIV Protease Inhibitors | 37 | 2020 | 430 | 5.760 |
Why?
|
| Adenine | 32 | 2023 | 936 | 4.600 |
Why?
|
| HIV-1 | 80 | 2022 | 6939 | 4.170 |
Why?
|
| Lamivudine | 23 | 2021 | 342 | 3.840 |
Why?
|
| Ritonavir | 26 | 2023 | 322 | 3.640 |
Why?
|
| AIDS-Related Opportunistic Infections | 22 | 2020 | 657 | 3.370 |
Why?
|
| Antiretroviral Therapy, Highly Active | 36 | 2020 | 1872 | 3.280 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 14 | 2022 | 215 | 3.050 |
Why?
|
| Anti-Retroviral Agents | 32 | 2024 | 1714 | 2.840 |
Why?
|
| Dideoxynucleosides | 19 | 2020 | 122 | 2.670 |
Why?
|
| CD4 Lymphocyte Count | 63 | 2020 | 2560 | 2.590 |
Why?
|
| Viral Load | 62 | 2023 | 3300 | 2.440 |
Why?
|
| Pneumonia, Pneumocystis | 6 | 2019 | 249 | 2.250 |
Why?
|
| Benzoxazines | 22 | 2023 | 301 | 2.220 |
Why?
|
| beta-Glucans | 5 | 2019 | 123 | 2.180 |
Why?
|
| Drug Resistance, Viral | 27 | 2020 | 820 | 2.120 |
Why?
|
| Pneumocystis carinii | 5 | 2019 | 74 | 2.010 |
Why?
|
| Deoxycytidine | 13 | 2015 | 826 | 1.690 |
Why?
|
| RNA, Viral | 37 | 2020 | 2901 | 1.600 |
Why?
|
| Oxazines | 17 | 2021 | 298 | 1.540 |
Why?
|
| Oligopeptides | 15 | 2015 | 1189 | 1.540 |
Why?
|
| Pyridones | 19 | 2024 | 711 | 1.470 |
Why?
|
| Acquired Immunodeficiency Syndrome | 16 | 2014 | 2232 | 1.340 |
Why?
|
| Drug Combinations | 24 | 2022 | 1958 | 1.220 |
Why?
|
| HIV Integrase Inhibitors | 7 | 2024 | 142 | 1.130 |
Why?
|
| Drug Approval | 6 | 2008 | 742 | 1.130 |
Why?
|
| Cyclohexanes | 5 | 2010 | 152 | 1.120 |
Why?
|
| Sulfonamides | 10 | 2012 | 1940 | 1.110 |
Why?
|
| Alkynes | 21 | 2021 | 306 | 1.080 |
Why?
|
| Alanine | 13 | 2022 | 572 | 1.070 |
Why?
|
| Drug Therapy, Combination | 44 | 2022 | 6489 | 1.070 |
Why?
|
| Triazoles | 9 | 2021 | 908 | 1.050 |
Why?
|
| Pyridines | 15 | 2014 | 2825 | 1.050 |
Why?
|
| Cyclopropanes | 21 | 2021 | 416 | 1.040 |
Why?
|
| Nevirapine | 5 | 2010 | 267 | 1.030 |
Why?
|
| Carbamates | 6 | 2020 | 196 | 1.030 |
Why?
|
| HIV | 16 | 2021 | 1604 | 1.030 |
Why?
|
| Communicable Diseases | 2 | 2023 | 880 | 0.960 |
Why?
|
| Rosa | 1 | 2022 | 8 | 0.870 |
Why?
|
| Humans | 303 | 2024 | 744366 | 0.850 |
Why?
|
| Disease Transmission, Infectious | 3 | 2020 | 547 | 0.850 |
Why?
|
| Health Care Sector | 1 | 2023 | 194 | 0.800 |
Why?
|
| Quinolones | 5 | 2017 | 367 | 0.800 |
Why?
|
| Drug Administration Schedule | 19 | 2020 | 4933 | 0.750 |
Why?
|
| Piperazines | 14 | 2022 | 2488 | 0.660 |
Why?
|
| HIV Seropositivity | 6 | 2019 | 971 | 0.640 |
Why?
|
| Pyridazines | 3 | 2008 | 202 | 0.620 |
Why?
|
| Double-Blind Method | 26 | 2020 | 12025 | 0.620 |
Why?
|
| Cost-Benefit Analysis | 25 | 2021 | 5388 | 0.610 |
Why?
|
| Zidovudine | 6 | 2013 | 620 | 0.610 |
Why?
|
| Organizational Policy | 1 | 2020 | 429 | 0.610 |
Why?
|
| Amides | 5 | 2022 | 459 | 0.610 |
Why?
|
| Pyrrolidinones | 6 | 2009 | 117 | 0.590 |
Why?
|
| Drug Substitution | 2 | 2020 | 281 | 0.570 |
Why?
|
| Medicine | 2 | 2023 | 946 | 0.540 |
Why?
|
| Adult | 119 | 2023 | 214052 | 0.540 |
Why?
|
| Antiviral Agents | 8 | 2023 | 2987 | 0.500 |
Why?
|
| Home Care Services | 1 | 2021 | 606 | 0.490 |
Why?
|
| Workplace | 1 | 2020 | 836 | 0.470 |
Why?
|
| Language | 1 | 2023 | 1471 | 0.460 |
Why?
|
| Pharmaceutical Preparations | 2 | 2023 | 1070 | 0.460 |
Why?
|
| Male | 129 | 2023 | 350115 | 0.450 |
Why?
|
| Thiazoles | 3 | 2015 | 1483 | 0.440 |
Why?
|
| Pneumonia, Viral | 3 | 2021 | 3242 | 0.440 |
Why?
|
| AIDS Serodiagnosis | 4 | 2011 | 184 | 0.430 |
Why?
|
| Female | 129 | 2023 | 380193 | 0.430 |
Why?
|
| Prodrugs | 1 | 2014 | 268 | 0.430 |
Why?
|
| Infectious Disease Transmission, Vertical | 7 | 2021 | 1320 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 16 | 2021 | 9955 | 0.380 |
Why?
|
| HLA-B Antigens | 2 | 2010 | 354 | 0.380 |
Why?
|
| Lipodystrophy | 4 | 2005 | 147 | 0.370 |
Why?
|
| Hepatitis C | 8 | 2020 | 1591 | 0.370 |
Why?
|
| Drug Costs | 8 | 2020 | 1105 | 0.360 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2010 | 213 | 0.360 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2010 | 63 | 0.360 |
Why?
|
| Middle Aged | 87 | 2023 | 213390 | 0.350 |
Why?
|
| HIV Fusion Inhibitors | 3 | 2007 | 81 | 0.340 |
Why?
|
| United States | 40 | 2024 | 69872 | 0.340 |
Why?
|
| Treatment Failure | 12 | 2019 | 2618 | 0.340 |
Why?
|
| Bone Density | 6 | 2017 | 3468 | 0.330 |
Why?
|
| West Nile Fever | 2 | 2019 | 81 | 0.330 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 3047 | 0.330 |
Why?
|
| Succinates | 1 | 2008 | 82 | 0.330 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2009 | 60 | 0.330 |
Why?
|
| Disease Management | 1 | 2019 | 2460 | 0.320 |
Why?
|
| Triterpenes | 1 | 2008 | 80 | 0.320 |
Why?
|
| Retroviridae | 1 | 2011 | 914 | 0.320 |
Why?
|
| Pyrimidinones | 4 | 2006 | 370 | 0.320 |
Why?
|
| Treatment Outcome | 38 | 2021 | 63107 | 0.310 |
Why?
|
| Clinical Trials as Topic | 16 | 2022 | 7914 | 0.310 |
Why?
|
| Anti-Infective Agents | 2 | 2007 | 974 | 0.290 |
Why?
|
| Fluorenes | 3 | 2020 | 160 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 7282 | 0.290 |
Why?
|
| DNA, Viral | 5 | 2014 | 2227 | 0.290 |
Why?
|
| Quality-Adjusted Life Years | 9 | 2020 | 1683 | 0.290 |
Why?
|
| Plasma | 4 | 2015 | 575 | 0.290 |
Why?
|
| Didanosine | 2 | 2005 | 153 | 0.290 |
Why?
|
| Fever | 1 | 2014 | 1616 | 0.280 |
Why?
|
| Mass Screening | 3 | 2021 | 5253 | 0.280 |
Why?
|
| Drug Monitoring | 1 | 2013 | 956 | 0.280 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2011 | 783 | 0.280 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2005 | 13 | 0.270 |
Why?
|
| Tablets | 2 | 2018 | 145 | 0.270 |
Why?
|
| Cardiovascular Diseases | 12 | 2020 | 15160 | 0.270 |
Why?
|
| Pyrones | 1 | 2005 | 36 | 0.270 |
Why?
|
| Drug Labeling | 1 | 2008 | 233 | 0.270 |
Why?
|
| Indinavir | 4 | 2002 | 74 | 0.270 |
Why?
|
| Virus Replication | 6 | 2020 | 2535 | 0.260 |
Why?
|
| Anus Diseases | 1 | 2005 | 59 | 0.260 |
Why?
|
| Cytidine Triphosphate | 1 | 2005 | 17 | 0.260 |
Why?
|
| Administration, Oral | 4 | 2018 | 3914 | 0.260 |
Why?
|
| Asthma | 2 | 2023 | 6010 | 0.260 |
Why?
|
| Life Expectancy | 10 | 2017 | 1184 | 0.250 |
Why?
|
| HIV Antibodies | 4 | 2014 | 1322 | 0.250 |
Why?
|
| Pandemics | 4 | 2022 | 8385 | 0.250 |
Why?
|
| Diketopiperazines | 1 | 2024 | 20 | 0.250 |
Why?
|
| HIV Envelope Protein gp41 | 2 | 2006 | 314 | 0.240 |
Why?
|
| Placebos | 6 | 2018 | 1676 | 0.230 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2000 | 76 | 0.230 |
Why?
|
| Fractures, Bone | 3 | 2011 | 1947 | 0.230 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2004 | 84 | 0.230 |
Why?
|
| Travel | 3 | 2020 | 788 | 0.230 |
Why?
|
| Hepatitis | 1 | 2005 | 227 | 0.230 |
Why?
|
| Osteoporosis | 2 | 2011 | 1579 | 0.230 |
Why?
|
| Risk Factors | 23 | 2023 | 72296 | 0.230 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 4 | 2012 | 138 | 0.230 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 743 | 0.230 |
Why?
|
| Proteinuria | 3 | 2016 | 658 | 0.230 |
Why?
|
| Medication Adherence | 5 | 2017 | 2063 | 0.220 |
Why?
|
| Health Facility Merger | 1 | 2023 | 53 | 0.220 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3135 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 4424 | 0.220 |
Why?
|
| Remission Induction | 1 | 2008 | 2385 | 0.220 |
Why?
|
| Benzimidazoles | 3 | 2020 | 850 | 0.220 |
Why?
|
| Ribavirin | 3 | 2020 | 395 | 0.220 |
Why?
|
| Patient Care Management | 1 | 2006 | 306 | 0.220 |
Why?
|
| Inflammation | 5 | 2018 | 10637 | 0.220 |
Why?
|
| Antitubercular Agents | 2 | 2009 | 1320 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3203 | 0.210 |
Why?
|
| Glucuronosyltransferase | 2 | 2012 | 128 | 0.210 |
Why?
|
| Computer Simulation | 10 | 2017 | 6194 | 0.210 |
Why?
|
| Hepatitis B Antibodies | 4 | 2009 | 159 | 0.210 |
Why?
|
| Viremia | 6 | 2020 | 736 | 0.210 |
Why?
|
| Diarrhea | 2 | 2019 | 1348 | 0.210 |
Why?
|
| Genotype | 12 | 2020 | 12952 | 0.200 |
Why?
|
| Herpesvirus 4, Human | 2 | 2004 | 1041 | 0.200 |
Why?
|
| Aging | 2 | 2020 | 8664 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2017 | 3444 | 0.200 |
Why?
|
| Drug Resistance, Microbial | 2 | 2003 | 862 | 0.200 |
Why?
|
| Patient Compliance | 7 | 2014 | 2684 | 0.190 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 1877 | 0.190 |
Why?
|
| Cerebrospinal Fluid | 1 | 2004 | 535 | 0.190 |
Why?
|
| Fomites | 1 | 2020 | 13 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2015 | 10252 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 789 | 0.190 |
Why?
|
| Congresses as Topic | 1 | 2005 | 764 | 0.190 |
Why?
|
| Nelfinavir | 2 | 2002 | 68 | 0.190 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3778 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 2765 | 0.190 |
Why?
|
| Young Adult | 22 | 2020 | 56429 | 0.190 |
Why?
|
| Syphilis | 1 | 2003 | 227 | 0.180 |
Why?
|
| Leukemia | 1 | 2008 | 1510 | 0.180 |
Why?
|
| Sick Leave | 1 | 2021 | 110 | 0.180 |
Why?
|
| Microsporida | 2 | 1999 | 6 | 0.180 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2020 | 52 | 0.180 |
Why?
|
| Hepatitis C, Chronic | 3 | 2020 | 1031 | 0.180 |
Why?
|
| Erectile Dysfunction | 2 | 2002 | 461 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2012 | 3444 | 0.180 |
Why?
|
| Cohort Studies | 21 | 2023 | 40559 | 0.180 |
Why?
|
| Aspergillosis | 2 | 2000 | 235 | 0.170 |
Why?
|
| Chemoprevention | 2 | 2014 | 319 | 0.170 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 674 | 0.170 |
Why?
|
| Drugs, Generic | 2 | 2015 | 421 | 0.170 |
Why?
|
| Uridine Monophosphate | 2 | 2020 | 70 | 0.170 |
Why?
|
| Equipment Contamination | 1 | 2020 | 185 | 0.170 |
Why?
|
| Phosphorous Acids | 1 | 2018 | 3 | 0.170 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 3537 | 0.170 |
Why?
|
| Antifungal Agents | 2 | 2008 | 729 | 0.170 |
Why?
|
| Neurotransmitter Transport Proteins | 1 | 2018 | 3 | 0.170 |
Why?
|
| Women | 1 | 2021 | 230 | 0.170 |
Why?
|
| Plant Extracts | 1 | 2022 | 471 | 0.170 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 78 | 0.170 |
Why?
|
| United States Food and Drug Administration | 4 | 2007 | 1584 | 0.160 |
Why?
|
| Health Maintenance Organizations | 1 | 2001 | 642 | 0.160 |
Why?
|
| Absorptiometry, Photon | 3 | 2014 | 1725 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2022 | 402 | 0.160 |
Why?
|
| Saquinavir | 2 | 2002 | 28 | 0.160 |
Why?
|
| Drug Interactions | 4 | 2022 | 1460 | 0.160 |
Why?
|
| Virus Shedding | 1 | 2018 | 108 | 0.160 |
Why?
|
| Genitalia | 1 | 2018 | 112 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2022 | 393 | 0.160 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2018 | 178 | 0.160 |
Why?
|
| Bilirubin | 2 | 2017 | 425 | 0.160 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 791 | 0.160 |
Why?
|
| Mitochondria | 3 | 2019 | 3514 | 0.160 |
Why?
|
| Itraconazole | 1 | 1997 | 43 | 0.150 |
Why?
|
| AIDS Vaccines | 3 | 2016 | 938 | 0.150 |
Why?
|
| Aerosols | 1 | 2020 | 625 | 0.150 |
Why?
|
| Contact Tracing | 1 | 2020 | 273 | 0.150 |
Why?
|
| National Health Programs | 1 | 2001 | 445 | 0.150 |
Why?
|
| Dendritic Cells | 2 | 2020 | 2725 | 0.150 |
Why?
|
| Organic Chemicals | 3 | 2007 | 211 | 0.150 |
Why?
|
| Amphotericin B | 1 | 1997 | 137 | 0.150 |
Why?
|
| Bradycardia | 1 | 1999 | 307 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 1 | 2009 | 2647 | 0.150 |
Why?
|
| Asymptomatic Infections | 1 | 2018 | 128 | 0.150 |
Why?
|
| Metabolic Diseases | 4 | 2012 | 658 | 0.150 |
Why?
|
| Post-Exposure Prophylaxis | 2 | 2016 | 102 | 0.150 |
Why?
|
| Kidney Diseases | 2 | 2015 | 2148 | 0.150 |
Why?
|
| Hepatitis B | 4 | 2017 | 695 | 0.150 |
Why?
|
| Creatinine | 4 | 2015 | 1919 | 0.150 |
Why?
|
| Adipose Tissue | 4 | 2020 | 3280 | 0.140 |
Why?
|
| Proteoglycans | 2 | 2011 | 837 | 0.140 |
Why?
|
| Kidney | 2 | 2015 | 7184 | 0.140 |
Why?
|
| Office Visits | 1 | 2001 | 598 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2009 | 1912 | 0.140 |
Why?
|
| Fever of Unknown Origin | 1 | 2016 | 93 | 0.140 |
Why?
|
| Israel | 5 | 2001 | 796 | 0.140 |
Why?
|
| Furans | 2 | 2007 | 194 | 0.140 |
Why?
|
| Immunoglobulins | 1 | 1999 | 881 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2022 | 850 | 0.140 |
Why?
|
| Blastomyces | 1 | 2015 | 10 | 0.140 |
Why?
|
| Sensitivity and Specificity | 8 | 2011 | 14723 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 687 | 0.130 |
Why?
|
| Hepatitis B Vaccines | 2 | 2009 | 194 | 0.130 |
Why?
|
| Blastomycosis | 1 | 2015 | 16 | 0.130 |
Why?
|
| Hepatitis B Core Antigens | 3 | 2005 | 92 | 0.130 |
Why?
|
| Patents as Topic | 1 | 2016 | 103 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2004 | 895 | 0.130 |
Why?
|
| Leishmania mexicana | 1 | 2015 | 31 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1997 | 224 | 0.130 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1995 | 66 | 0.130 |
Why?
|
| RNA | 2 | 2023 | 2749 | 0.130 |
Why?
|
| Suicide | 2 | 2017 | 1474 | 0.130 |
Why?
|
| Chemistry, Clinical | 1 | 1995 | 64 | 0.130 |
Why?
|
| Pilot Projects | 6 | 2019 | 8319 | 0.130 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 6171 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13693 | 0.120 |
Why?
|
| Nitriles | 3 | 2008 | 955 | 0.120 |
Why?
|
| Blood Cell Count | 1 | 1995 | 403 | 0.120 |
Why?
|
| Insulin Resistance | 5 | 2019 | 3864 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1996 | 323 | 0.120 |
Why?
|
| Kidney Calculi | 1 | 1998 | 465 | 0.120 |
Why?
|
| Drug Utilization | 2 | 1992 | 1183 | 0.120 |
Why?
|
| Adiponectin | 2 | 2019 | 1101 | 0.120 |
Why?
|
| Cystatin C | 1 | 2015 | 250 | 0.120 |
Why?
|
| Albuminuria | 2 | 2016 | 681 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2006 | 5096 | 0.120 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2015 | 124 | 0.120 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2009 | 841 | 0.120 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 518 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 1381 | 0.120 |
Why?
|
| Bacterial Vaccines | 1 | 1996 | 403 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2020 | 1379 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 1400 | 0.110 |
Why?
|
| Disease Progression | 6 | 2021 | 13286 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2021 | 2026 | 0.110 |
Why?
|
| Aged | 24 | 2021 | 163288 | 0.110 |
Why?
|
| Viral Vaccines | 2 | 1996 | 636 | 0.110 |
Why?
|
| Health Policy | 3 | 2017 | 2661 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 804 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1996 | 629 | 0.110 |
Why?
|
| Lymphocyte Count | 1 | 1995 | 793 | 0.110 |
Why?
|
| Quality of Life | 7 | 2020 | 12802 | 0.110 |
Why?
|
| Mutation | 7 | 2019 | 29786 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 2016 | 477 | 0.100 |
Why?
|
| Disabled Persons | 2 | 2020 | 1212 | 0.100 |
Why?
|
| Nausea | 1 | 2015 | 674 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2023 | 1519 | 0.100 |
Why?
|
| Respiration Disorders | 1 | 2015 | 371 | 0.100 |
Why?
|
| Nose | 1 | 2015 | 509 | 0.100 |
Why?
|
| Leadership | 1 | 2021 | 1357 | 0.100 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 968 | 0.100 |
Why?
|
| Acyclovir | 2 | 2009 | 272 | 0.100 |
Why?
|
| Survival Rate | 3 | 2017 | 12788 | 0.100 |
Why?
|
| Adolescent | 16 | 2019 | 85779 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 15078 | 0.100 |
Why?
|
| Arthralgia | 1 | 2015 | 456 | 0.090 |
Why?
|
| Immunocompromised Host | 4 | 2019 | 847 | 0.090 |
Why?
|
| Cholesterol | 2 | 2014 | 2919 | 0.090 |
Why?
|
| Models, Economic | 2 | 2015 | 712 | 0.090 |
Why?
|
| Alprostadil | 1 | 1990 | 89 | 0.090 |
Why?
|
| Health Care Costs | 4 | 2015 | 3208 | 0.090 |
Why?
|
| Teratogens | 1 | 2011 | 112 | 0.090 |
Why?
|
| Weight Gain | 1 | 2020 | 2293 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 426 | 0.090 |
Why?
|
| Hepatitis B virus | 2 | 2003 | 513 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 258 | 0.090 |
Why?
|
| Comorbidity | 3 | 2020 | 10388 | 0.090 |
Why?
|
| Ambulatory Care | 1 | 2001 | 2708 | 0.090 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 141 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 1990 | 119 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 3 | 2015 | 2166 | 0.090 |
Why?
|
| Receptors, CCR5 | 2 | 2008 | 498 | 0.080 |
Why?
|
| Suicidal Ideation | 2 | 2017 | 1246 | 0.080 |
Why?
|
| Pregnancy | 10 | 2023 | 29144 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 1856 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 4386 | 0.080 |
Why?
|
| Guidelines as Topic | 3 | 2005 | 1405 | 0.080 |
Why?
|
| Access to Information | 1 | 2012 | 320 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 10943 | 0.080 |
Why?
|
| Sinusitis | 1 | 1997 | 923 | 0.080 |
Why?
|
| Vaccines, DNA | 1 | 2010 | 305 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 1912 | 0.080 |
Why?
|
| HIV Protease | 1 | 2008 | 96 | 0.080 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2011 | 317 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 527 | 0.080 |
Why?
|
| State Government | 1 | 2011 | 372 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2017 | 23336 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 9274 | 0.080 |
Why?
|
| Confidentiality | 1 | 2012 | 612 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2017 | 4459 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 817 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 1989 | 214 | 0.080 |
Why?
|
| Pyrimidines | 3 | 2008 | 2943 | 0.070 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 4925 | 0.070 |
Why?
|
| Headache | 1 | 2015 | 1226 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 1513 | 0.070 |
Why?
|
| Brazil | 2 | 2015 | 1270 | 0.070 |
Why?
|
| Histamine H2 Antagonists | 1 | 2008 | 165 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1995 | 1837 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2020 | 4479 | 0.070 |
Why?
|
| Clofibric Acid | 1 | 2006 | 8 | 0.070 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2006 | 90 | 0.070 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 12961 | 0.070 |
Why?
|
| Clinical Protocols | 3 | 2009 | 1461 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2017 | 3084 | 0.070 |
Why?
|
| Sputum | 1 | 2008 | 476 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 768 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2001 | 1821 | 0.070 |
Why?
|
| Time Factors | 11 | 2014 | 40075 | 0.070 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 1004 | 0.070 |
Why?
|
| Public Policy | 1 | 2010 | 572 | 0.070 |
Why?
|
| Retrospective Studies | 10 | 2023 | 77460 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1739 | 0.070 |
Why?
|
| Lupus Nephritis | 2 | 2019 | 310 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1620 | 0.070 |
Why?
|
| Models, Biological | 4 | 2019 | 9584 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 10183 | 0.070 |
Why?
|
| Body Composition | 2 | 2013 | 2402 | 0.070 |
Why?
|
| Models, Statistical | 4 | 2017 | 5101 | 0.070 |
Why?
|
| Incidence | 6 | 2019 | 20952 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2009 | 6366 | 0.060 |
Why?
|
| Zalcitabine | 1 | 2005 | 42 | 0.060 |
Why?
|
| Blood Glucose | 4 | 2014 | 6254 | 0.060 |
Why?
|
| Antigen Presentation | 1 | 2010 | 1284 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2023 | 39052 | 0.060 |
Why?
|
| Condoms | 1 | 2006 | 323 | 0.060 |
Why?
|
| Liver Function Tests | 2 | 2016 | 528 | 0.060 |
Why?
|
| Insurance Benefits | 2 | 1996 | 183 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 1995 | 2119 | 0.060 |
Why?
|
| Informed Consent | 1 | 2011 | 995 | 0.060 |
Why?
|
| Myocardial Infarction | 3 | 2017 | 11718 | 0.060 |
Why?
|
| Delivery of Health Care | 3 | 2012 | 5321 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 2274 | 0.060 |
Why?
|
| Lipids | 3 | 2012 | 3307 | 0.060 |
Why?
|
| Recurrence | 2 | 2014 | 8340 | 0.060 |
Why?
|
| Homozygote | 1 | 2008 | 1787 | 0.060 |
Why?
|
| Veterans | 1 | 2017 | 2519 | 0.060 |
Why?
|
| Genes, pol | 1 | 2003 | 51 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 6486 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2012 | 1058 | 0.060 |
Why?
|
| Europe | 1 | 2010 | 3338 | 0.060 |
Why?
|
| Patient Selection | 1 | 1996 | 4216 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 15520 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2012 | 2566 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5135 | 0.060 |
Why?
|
| HIV Seroprevalence | 1 | 2003 | 86 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 1 | 2008 | 526 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2014 | 2897 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2012 | 6459 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1990 | 1131 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 57776 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12244 | 0.050 |
Why?
|
| Fats | 1 | 2003 | 102 | 0.050 |
Why?
|
| Body Weight | 1 | 2013 | 4671 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 25039 | 0.050 |
Why?
|
| Glycolates | 1 | 1982 | 40 | 0.050 |
Why?
|
| Prospective Studies | 10 | 2021 | 53290 | 0.050 |
Why?
|
| Clindamycin | 1 | 2022 | 139 | 0.050 |
Why?
|
| Prognosis | 4 | 2017 | 29060 | 0.050 |
Why?
|
| Health Expenditures | 2 | 1992 | 2349 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2010 | 1240 | 0.050 |
Why?
|
| Risk | 2 | 2012 | 9688 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2009 | 1904 | 0.050 |
Why?
|
| Costs and Cost Analysis | 3 | 1996 | 1680 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2010 | 2488 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2009 | 1186 | 0.050 |
Why?
|
| HIV Antigens | 2 | 2014 | 347 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 1265 | 0.050 |
Why?
|
| Punctures | 1 | 2003 | 374 | 0.050 |
Why?
|
| Paronychia | 1 | 2001 | 11 | 0.050 |
Why?
|
| Antibodies, Heterophile | 1 | 2001 | 126 | 0.050 |
Why?
|
| Hypertriglyceridemia | 1 | 2004 | 293 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 604 | 0.050 |
Why?
|
| Infectious Mononucleosis | 1 | 2001 | 131 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2016 | 3309 | 0.050 |
Why?
|
| Specialization | 1 | 2006 | 776 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 476 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6539 | 0.050 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 5524 | 0.050 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2000 | 25 | 0.050 |
Why?
|
| Fumarates | 1 | 2021 | 132 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 1851 | 0.050 |
Why?
|
| Sex Ratio | 1 | 2021 | 110 | 0.050 |
Why?
|
| Obesity | 2 | 2020 | 12746 | 0.050 |
Why?
|
| Models, Theoretical | 4 | 2019 | 3589 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 213 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 275 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2005 | 895 | 0.050 |
Why?
|
| Mycobacterium avium Complex | 1 | 2000 | 60 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2006 | 727 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1990 | 2282 | 0.050 |
Why?
|
| Candidiasis, Oral | 1 | 2000 | 60 | 0.040 |
Why?
|
| Hypoglycemic Agents | 2 | 2004 | 2873 | 0.040 |
Why?
|
| International Agencies | 1 | 2020 | 240 | 0.040 |
Why?
|
| Glucocorticoids | 3 | 2016 | 2108 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 105 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 884 | 0.040 |
Why?
|
| Acidosis, Lactic | 1 | 2001 | 142 | 0.040 |
Why?
|
| Hospitalization | 3 | 2021 | 10259 | 0.040 |
Why?
|
| Eating | 2 | 1996 | 1536 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2012 | 2494 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 871 | 0.040 |
Why?
|
| Microsporidiosis | 1 | 1999 | 23 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2008 | 2241 | 0.040 |
Why?
|
| Syndrome | 1 | 2005 | 3252 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 1182 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2006 | 1125 | 0.040 |
Why?
|
| West Nile virus | 1 | 2019 | 82 | 0.040 |
Why?
|
| Jews | 1 | 2001 | 385 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2007 | 1401 | 0.040 |
Why?
|
| Fees, Pharmaceutical | 1 | 2018 | 64 | 0.040 |
Why?
|
| Budgets | 1 | 2020 | 229 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 294 | 0.040 |
Why?
|
| Bile | 1 | 1999 | 299 | 0.040 |
Why?
|
| Vaccination | 1 | 2010 | 3279 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 2019 | 189 | 0.040 |
Why?
|
| Meningitis | 1 | 2019 | 216 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2005 | 1504 | 0.040 |
Why?
|
| Virology | 1 | 2017 | 77 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 1151 | 0.040 |
Why?
|
| Caffeine | 1 | 1982 | 699 | 0.040 |
Why?
|
| Immunoglobulin G | 2 | 2007 | 4561 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2007 | 1338 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2017 | 106 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 109 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 3020 | 0.040 |
Why?
|
| Stavudine | 1 | 1996 | 85 | 0.040 |
Why?
|
| Neural Tube Defects | 1 | 2019 | 256 | 0.040 |
Why?
|
| Insect Repellents | 1 | 1996 | 17 | 0.040 |
Why?
|
| Biological Availability | 1 | 2017 | 397 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2001 | 880 | 0.040 |
Why?
|
| Lung | 1 | 2015 | 9857 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2000 | 316 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 1677 | 0.040 |
Why?
|
| Data Collection | 3 | 2010 | 3339 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2019 | 2104 | 0.040 |
Why?
|
| Aspergillus fumigatus | 1 | 1997 | 150 | 0.040 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 2795 | 0.030 |
Why?
|
| Seizures | 1 | 2009 | 2859 | 0.030 |
Why?
|
| Professional Staff Committees | 1 | 1996 | 38 | 0.030 |
Why?
|
| Labor, Obstetric | 1 | 1999 | 333 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2006 | 1862 | 0.030 |
Why?
|
| Gloves, Protective | 1 | 1995 | 22 | 0.030 |
Why?
|
| Anorexia | 1 | 2016 | 161 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2001 | 985 | 0.030 |
Why?
|
| Animals, Domestic | 1 | 1995 | 56 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 2019 | 470 | 0.030 |
Why?
|
| Research Personnel | 1 | 2021 | 573 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2021 | 25628 | 0.030 |
Why?
|
| Food Microbiology | 1 | 1995 | 78 | 0.030 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 1995 | 58 | 0.030 |
Why?
|
| Antigens, Fungal | 1 | 2015 | 70 | 0.030 |
Why?
|
| Hemophilia A | 1 | 1998 | 351 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2007 | 3712 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2000 | 729 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 1995 | 191 | 0.030 |
Why?
|
| Biopsy | 2 | 2018 | 6755 | 0.030 |
Why?
|
| Amylases | 1 | 1995 | 173 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2020 | 810 | 0.030 |
Why?
|
| Prisoners | 1 | 1998 | 297 | 0.030 |
Why?
|
| Chickenpox | 1 | 1995 | 131 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2005 | 6621 | 0.030 |
Why?
|
| Stroke | 1 | 2017 | 9981 | 0.030 |
Why?
|
| Acute Disease | 4 | 2010 | 7147 | 0.030 |
Why?
|
| Rural Health | 1 | 1996 | 305 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2019 | 652 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 1607 | 0.030 |
Why?
|
| Electrolytes | 1 | 1995 | 282 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 1453 | 0.030 |
Why?
|
| Cats | 1 | 1995 | 1000 | 0.030 |
Why?
|
| Immunity, Innate | 2 | 2020 | 2962 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 380 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2018 | 775 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 20130 | 0.030 |
Why?
|
| Minerals | 1 | 1995 | 275 | 0.030 |
Why?
|
| South Africa | 1 | 2019 | 1731 | 0.030 |
Why?
|
| Hospitals | 2 | 2022 | 3954 | 0.030 |
Why?
|
| Haemophilus Infections | 1 | 1993 | 95 | 0.030 |
Why?
|
| Metformin | 1 | 2000 | 836 | 0.030 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 246 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 1837 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 689 | 0.030 |
Why?
|
| Research Design | 1 | 2009 | 5984 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2020 | 19233 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2021 | 1695 | 0.030 |
Why?
|
| Haemophilus influenzae | 1 | 1993 | 172 | 0.030 |
Why?
|
| Cough | 1 | 2016 | 555 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2006 | 3531 | 0.030 |
Why?
|
| Primary Health Care | 2 | 2006 | 4557 | 0.030 |
Why?
|
| Chromatography | 1 | 1992 | 206 | 0.030 |
Why?
|
| Population Growth | 1 | 1992 | 52 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2013 | 356 | 0.030 |
Why?
|
| Jaundice | 1 | 2012 | 89 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1995 | 389 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 610 | 0.030 |
Why?
|
| Triglycerides | 1 | 2020 | 2453 | 0.030 |
Why?
|
| Gestational Age | 1 | 2021 | 3493 | 0.030 |
Why?
|
| Health Status | 1 | 2005 | 4034 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2023 | 3107 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2014 | 15297 | 0.030 |
Why?
|
| Laboratories | 1 | 1995 | 463 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 441 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1677 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2012 | 99 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2023 | 4576 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2569 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2133 | 0.020 |
Why?
|
| Public Sector | 1 | 1992 | 265 | 0.020 |
Why?
|
| Fatigue | 1 | 2018 | 1531 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 3255 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4189 | 0.020 |
Why?
|
| Child | 5 | 2023 | 77709 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2596 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2017 | 3587 | 0.020 |
Why?
|
| Duodenal Ulcer | 1 | 1990 | 125 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 1990 | 125 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 232 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 3177 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 126 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 1681 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 537 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 19905 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1660 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2020 | 3759 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 244 | 0.020 |
Why?
|
| Radiography | 2 | 2015 | 7023 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 3873 | 0.020 |
Why?
|
| Private Sector | 1 | 1992 | 392 | 0.020 |
Why?
|
| Minority Groups | 1 | 1997 | 1221 | 0.020 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2009 | 27 | 0.020 |
Why?
|
| Misoprostol | 1 | 1990 | 95 | 0.020 |
Why?
|
| Hyperinsulinism | 2 | 2004 | 415 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1997 | 5181 | 0.020 |
Why?
|
| Consent Forms | 1 | 2009 | 53 | 0.020 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 23 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3743 | 0.020 |
Why?
|
| Decision Trees | 1 | 1990 | 506 | 0.020 |
Why?
|
| Homosexuality | 1 | 2009 | 262 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2012 | 723 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12356 | 0.020 |
Why?
|
| Cost Savings | 1 | 2013 | 925 | 0.020 |
Why?
|
| Massachusetts | 2 | 2012 | 8662 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2003 | 6077 | 0.020 |
Why?
|
| Logistic Models | 2 | 2015 | 13409 | 0.020 |
Why?
|
| Morbidity | 1 | 2013 | 1768 | 0.020 |
Why?
|
| Homeostasis | 1 | 2019 | 3339 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 1793 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 15535 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 1989 | 206 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2009 | 221 | 0.020 |
Why?
|
| Dyspnea | 1 | 2015 | 1303 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1127 | 0.020 |
Why?
|
| Information Systems | 1 | 1989 | 410 | 0.020 |
Why?
|
| Cell Line | 2 | 2017 | 16000 | 0.020 |
Why?
|
| Drug and Narcotic Control | 1 | 1988 | 146 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 3966 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4666 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2010 | 3207 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 1990 | 935 | 0.020 |
Why?
|
| Bacteremia | 1 | 1993 | 963 | 0.020 |
Why?
|
| Reoviridae | 1 | 2006 | 161 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 4153 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3553 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 1020 | 0.020 |
Why?
|
| Suicide, Attempted | 1 | 2014 | 1218 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 7721 | 0.020 |
Why?
|
| Developed Countries | 1 | 2009 | 437 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1999 | 6442 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2010 | 13991 | 0.020 |
Why?
|
| Nucleosides | 1 | 2006 | 138 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8091 | 0.020 |
Why?
|
| Circumcision, Male | 1 | 2007 | 150 | 0.020 |
Why?
|
| Mortality | 1 | 1997 | 2864 | 0.020 |
Why?
|
| Prevalence | 3 | 2008 | 15221 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4554 | 0.020 |
Why?
|
| DNA | 1 | 2019 | 7294 | 0.020 |
Why?
|
| Victoria | 1 | 2004 | 67 | 0.020 |
Why?
|
| Probability | 1 | 1990 | 2506 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 595 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2006 | 214 | 0.020 |
Why?
|
| Family | 1 | 1995 | 3147 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 1737 | 0.020 |
Why?
|
| Decision Making | 1 | 1998 | 3888 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7182 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 12207 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 2779 | 0.010 |
Why?
|
| Linear Models | 1 | 2014 | 5953 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9445 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2014 | 2585 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1999 | 4446 | 0.010 |
Why?
|
| Life Style | 1 | 1995 | 3835 | 0.010 |
Why?
|
| Cause of Death | 1 | 2014 | 3582 | 0.010 |
Why?
|
| Age Factors | 1 | 2020 | 18373 | 0.010 |
Why?
|
| American Heart Association | 1 | 2008 | 1057 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 1205 | 0.010 |
Why?
|
| Developing Countries | 2 | 2009 | 2815 | 0.010 |
Why?
|
| Demography | 1 | 1988 | 1655 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 2375 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2003 | 305 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2010 | 4010 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 35425 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2020 | 12721 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2012 | 6542 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2015 | 9849 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2004 | 402 | 0.010 |
Why?
|
| Body Constitution | 1 | 2002 | 278 | 0.010 |
Why?
|
| Genomics | 1 | 2018 | 5717 | 0.010 |
Why?
|
| Chemistry | 1 | 1982 | 352 | 0.010 |
Why?
|
| Animals | 4 | 2020 | 168768 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1982 | 518 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1998 | 4257 | 0.010 |
Why?
|
| Drug Stability | 1 | 1982 | 291 | 0.010 |
Why?
|
| Fracture Fixation | 1 | 2004 | 354 | 0.010 |
Why?
|
| Gene Products, vpr | 1 | 2001 | 36 | 0.010 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 39 | 0.010 |
Why?
|
| Solutions | 1 | 1982 | 426 | 0.010 |
Why?
|
| Health Services | 1 | 2006 | 758 | 0.010 |
Why?
|
| Pain | 1 | 2016 | 4988 | 0.010 |
Why?
|
| Liver | 1 | 2016 | 7475 | 0.010 |
Why?
|
| Smoking | 1 | 2017 | 8987 | 0.010 |
Why?
|
| Thermodynamics | 1 | 1982 | 594 | 0.010 |
Why?
|
| Methotrexate | 1 | 2007 | 1728 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2010 | 5451 | 0.010 |
Why?
|
| Patient Simulation | 1 | 2002 | 309 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2006 | 1275 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1982 | 626 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10400 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 4034 | 0.010 |
Why?
|
| Azure Stains | 1 | 1999 | 5 | 0.010 |
Why?
|
| Spores | 1 | 1999 | 15 | 0.010 |
Why?
|
| Alleles | 1 | 2010 | 6933 | 0.010 |
Why?
|
| New England | 1 | 2002 | 1022 | 0.010 |
Why?
|
| Outpatients | 1 | 2006 | 1487 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 1988 | 1637 | 0.010 |
Why?
|
| Microbiological Techniques | 1 | 1999 | 102 | 0.010 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1997 | 99 | 0.010 |
Why?
|
| HIV Core Protein p24 | 1 | 1997 | 256 | 0.010 |
Why?
|
| Forecasting | 1 | 2006 | 2951 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13814 | 0.010 |
Why?
|
| Boston | 1 | 2010 | 9312 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 11726 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2012 | 4369 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2001 | 1537 | 0.010 |
Why?
|
| Managed Care Programs | 1 | 2002 | 950 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2891 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 18111 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2000 | 1655 | 0.010 |
Why?
|
| Insulin | 2 | 2000 | 6582 | 0.010 |
Why?
|
| Temperature | 1 | 1982 | 2204 | 0.010 |
Why?
|
| Urban Population | 1 | 2003 | 2022 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 2660 | 0.010 |
Why?
|
| Inpatients | 1 | 2006 | 2518 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10483 | 0.010 |
Why?
|
| Epitopes | 1 | 2001 | 2571 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2000 | 1813 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1997 | 1369 | 0.010 |
Why?
|
| Social Class | 1 | 2002 | 1997 | 0.010 |
Why?
|
| Chemokines | 1 | 1997 | 970 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 20824 | 0.010 |
Why?
|
| Maintenance | 1 | 1992 | 25 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 1622 | 0.010 |
Why?
|
| Brain | 1 | 2019 | 26388 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 6111 | 0.010 |
Why?
|
| Atrial Fibrillation | 1 | 1990 | 5035 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12262 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1997 | 1348 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 7658 | 0.010 |
Why?
|
| Computers | 1 | 1992 | 612 | 0.010 |
Why?
|
| Quality Control | 1 | 1992 | 841 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12797 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 6100 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 9145 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 1423 | 0.000 |
Why?
|
| Coronary Circulation | 1 | 1990 | 1572 | 0.000 |
Why?
|
| Infant | 1 | 2005 | 35134 | 0.000 |
Why?
|
| ROC Curve | 1 | 1990 | 3528 | 0.000 |
Why?
|